EICHOR
● Active Not Recruiting
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Condition: Lung Cancer Metastatic · Renal Cell Carcinoma · Head and Neck Cancer · Sponsor: UNICANCER
About this study
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers. However, the optimal duration of immunotherapies is currently unknown. Our hypothesis is that a reduced dose intensity of IO could be as effective as the current standard treatment in term of prevention of the disease progression. If proved right, this study will have a positive medico-economic impact by reduction of the costs associated with the treatment and the toxicity, and an increase of the patients' quality of life.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (33)
| Institut de cancérologie de l'Ouest | Angers, France | — |
| Clinique Sainte Catherine | Avignon, France | — |
| Centre Hospitalier de la Côte Basque | Bayonne, France | — |
| CHU Bordeaux - Hôpial Saint André | Bordeaux, France | — |
| CH Boulogne sur Mer | Boulogne-sur-Mer, France | — |
| Centre François Baclesse | Caen, France | — |
| Centre Jean Perrin | Clermont-Ferrand, France | — |
| Centre Hospitalier Intercommunal | Créteil, France | — |
| CHU Henri Mondor | Créteil, France | — |
| Centre Georges François Leclerc | Dijon, France | — |
| GH Mutualiste de Grenoble | Grenoble, France | — |
| CHD Vendée | La Roche-sur-Yon, France | — |
+ 21 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05078047